glp-1 myths medications are often misunderstood. Our goal is to provide clear, reliable information so patients can better understand their options for weight management support. Swipe to explore common and facts. To Unpacking the Truth Behind GLP-1

Key FDA guidance: Incremental weight loss (enobosarm + GLP-1 versus GLP-1 alone) is an acceptable primary endpoint for approval The 3 mg dose is appropriate for continued development FDA encouraged including younger patients, not just older populations Phase 2 QUALITY study data: 16 weeks of enobosarm in older patients taking semaglutide Preserved lean mass and burned additional fat mass Improved physical function During the maintenance period (12 weeks after semaglutide discontinuation), enobosarm prevented weight regain by 46% compared to placebo Next steps : Veru plans to initiate the Phase 2b PLATEAU trial in Q1 2026, enrolling approximately 180 patients (both older and younger) with obesity taking tirzepatide

Why in-person monitoring matters Telehealth GLP-1 prescribers have made these medications more accessible, and that is a positive development

Hadidchi will conduct a thorough evaluation of your medical history, current health status, and treatment goals to ensure the best and safest care

If you're looking for a clinician trained in this systems-based approach, you can explore the FMU Doctor Graduate List a directory of certified practitioners worldwide who practice Functional Medicine 2.0

Taking GLP-1s has been shown to reduce markers of inflammation

The study included patients who initiated a GLP-1 RA or GIP/GLP-1 RA between January 1, 2015, and December 31, 2024